New Delhi: Amid rising concerns over the misuse and unauthorized sale of weight-loss medications, the Ministry of Health and Family Welfare has stepped up regulatory oversight to ensure ethical practices across the pharmaceutical supply chain.
In a recent statement, the ministry said that the Drugs Controller General of India has intensified surveillance on the distribution and promotion of GLP-1-based weight-loss drugs. The move comes in response to reports suggesting potential irregularities in how these medications are being marketed and sold.
Officials confirmed that the Drugs Controller, in coordination with state-level regulators, has launched targeted enforcement measures aimed at curbing unauthorized access and preventing misuse. The focus is on monitoring the entire supply chain—from manufacturers and distributors to retailers—to ensure compliance with existing norms.
The government reiterated that the drug has been approved in India under strict conditions. It can only be prescribed by specialists such as endocrinologists and internal medicine experts, and in certain cases, by cardiologists depending on the medical indication. Authorities stressed that any deviation from these guidelines would be treated as a serious violation.
Health officials also warned that enforcement efforts will continue to intensify in the coming weeks. Non-compliance could invite stringent action, including suspension or cancellation of licenses, financial penalties, and legal prosecution under applicable laws.
The ministry’s action signals a broader push to regulate the fast-growing market for weight-loss treatments, particularly as demand for such drugs continues to rise. Authorities have urged stakeholders in the pharmaceutical sector to adhere strictly to prescribed norms to safeguard patient safety and maintain ethical standards.
